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Abstract: Terrestrial actinomycetes are noteworthy producers of a multitude of antibiotics, 
however the marine representatives are much less studied in this regard. In this study,  
90 actinomycetes were isolated from 11 different species of marine sponges that had been 
collected from offshore Ras Mohamed (Egypt) and from Rovinj (Croatia). Phylogenetic 
characterization of the isolates based on 16S rRNA gene sequencing supported their 
assignment to 18 different actinomycete genera representing seven different suborders. 
Fourteen putatively novel species were identified based on sequence similarity values 
below 98.2% to other strains in the NCBI database. A putative new genus related to 
Rubrobacter was isolated on M1 agar that had been amended with sponge extract, thus 
highlighting the need for innovative cultivation protocols. Testing for anti-infective 
activities was performed against clinically relevant, Gram-positive (Enterococcus faecalis, 
Staphylococcus aureus) and Gram-negative (Escherichia coli, Pseudomonas aeruginosa) 
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bacteria, fungi (Candida albicans) and human parasites (Leishmania major, Trypanosoma 
brucei). Bioactivities against these pathogens were documented for 10 actinomycete 
isolates. These results show a high diversity of actinomycetes associated with marine 
sponges as well as highlight their potential to produce anti-infective agents.  
Keywords: actinomycetes; marine sponges; anti-infective; anti-parasitic; phylogenetic 
analysis 
 
1. Introduction 
Infectious disease is the number one cause of death in tropical countries accounting for 
approximately half of all fatalities. In addition, infectious disease mortality rates are also increasing in 
developed countries [1]. Emerging and re-emerging infections are thought to be driven largely by 
socio-economic, environmental and ecological factors [2–4]. Jones et al. reported the emergence of 
335 infectious diseases between 1940 and 2004 in the global human population [5]. These negative 
health trends call for a renewed interest in infectious disease as well as effective strategies for 
treatment and prevention. With respect to the development of new antimicrobials, the marine 
environment holds great promise for the discovery of novel bioactive compounds.  
Marine sponges (phylum Porifera) are among the most ancient multicellular animals (metazoans). 
These sessile, filter feeding animals are a rich source of novel biologically active metabolites and offer 
great potential for drug discovery and, in the long term, for treatment of cancer and infectious diseases [6]. 
Sponges are also known to have intimate contact with various types of microorganisms such as 
viruses, bacteria, archaea, fungi, protozoa and single-celled algae, and the nature of the sponge-
microbe interaction is manifold [7,8]. In general terms, microorganisms serve as food particles, which 
are retained from seawater in the choanocyte chambers, translocated into the mesohyl interior and 
digested by phagocytosis. Many sponges contain furthermore symbiotic microbial consortia within 
their mesohyl matrix that may amount up to nearly half of their biomass. The implementation of the 
16S rRNA gene as a phylogenetic marker has, over the last decade, provided unprecedented insights 
into the microbiology of sponges [7,8]. As many as 18 different prokaryotic phyla and one candidate 
phylum were so far discovered from sponges, the vast majority of which remains unculturable to this 
date. Finally, sponges can be overgrown by microbial biofilms and can even succumb to infections 
much like has been reported for corals and other invertebrates [9].  
Members of the phylum Actinobacteria and specifically the order Actinomycetales have been 
identified as abundant members of sponge-associated microbial communities [10–15]. Their existence 
in the marine environment has been further shown in marine sediments as well as in the deepest ocean 
trenches [16–21]. Actinomycetes are of considerable interest owing to their ability to produce new 
chemical entities with diverse pharmacological activities. Marine actinomycetes in particular have 
yielded numerous novel secondary metabolites [22]. New actinomycete taxa of marine origin have also 
been recovered as best exemplified by Salinispora, the first marine obligate actinomycete isolated 
from ocean sediments [23] as well as from a sponge [24]. Our aim is to isolate and culture 
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actinomycetes from marine sponges and to characterize their potential to produce bioactive 
compounds, specifically those which inhibit the growth of human pathogens and parasites. 
2. Results and Discussion 
2.1. Diversity of Sponge-Associated Actinomycetes 
Homogenates from 11 taxonomically different marine sponges collected from Ras Mohamed, Egypt 
and Rovinj, Croatia were plated on a range of selective media for the isolation of actinomycetes. 
Callyspongia aff. implexa yielded the highest number of isolates (22), followed by Aplysina 
aerophoba (16), Spheciospongia vagabunda (11), Hemimycale culumella (9), Hyrtios erecta (8), 
Dysidea tupha (6), Callyspongia sp. (6), Dysidea avara (4), Amphimedon sp. (4), Negombata 
magnifica (4), while no actinomycete strains were cultivated from Ircinia fasciculata (Figure 1A). A 
comparison of the nearly complete 16S rRNA gene sequences of 52 out of 90 putative actinobacterial 
strains isolated from these sponges against sequences in the NCBI GenBank database revealed the 
phylogenetic affiliations to 18 different genera representing 14 families and seven suborders 
(Supplementary Table 1). The highest number of isolates were found to be affiliated with the genus 
Mycobacterium (13), followed by Micrococcus (12), Micromonospora (11), Microbacterium (11), 
Brevibacterium (9), Kocuria (6), Corynebacterium (5), Rhodococcus (5), Brachybacterium (3), 
Rubrobacter (2), Streptomyces (2), Dietzia (2), Salinispora (2), Actinokineospora (2), Gordonia (2), 
Arthrobacter (1), Nocardiopsis (1) and Rothia (1) (Figure 1B). It has been reported that the genera 
belonging to Micromonospora, Rhodococcus and Streptomyces are the dominant actinobacterial 
genera in marine environments [25]. Representatives of all three taxa were isolated from the marine 
sponges studied here although other genera such as Mycobacterium, Micrococcus, Microbacterium 
were also represented by high numbers of isolates. 
Figure 1. Number of actinomycete isolates (A) per sponge species, (B) per actinomycete 
genera and (C) per cultivation media. 
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Figure 1. Cont. 
 
 
 
Given that less than 1% of bacteria associated with sponges can be cultured, the use of appropriate 
isolation media is critical for improving the recovery of actinobacteria [14]. The isolation media of this 
study were chosen to select for actinobacteria. M1 exhibited the highest recovery producing 27 isolates 
and MA recovered only two isolates (Figure 1C). In terms of diversity, M1 also produced isolates 
belonging to the highest number of genera (13), followed by ISP medium 2 (11 genera), R2A (eight 
genera), AIA (six genera), M1 plus (five genera), OLIGO (four genera), GAA (two genera), and the 
lowest diversity was observed with MA which recovered only one genus. This variation likely reflects 
the effect of media composition, which is consistent with previous observations [14,25]. Addition of 
aqueous sponge extract to M1 medium resulted in the isolation of a putatively new genus with 
Mar. Drugs 2010, 8 
 
403
Rubrobacter as its closest relative. This shows that variation from standard protocols is a worthwhile 
procedure. It was reported that media without added sponge extract produced the largest number of 
different colony morphotypes and the addition of sponge extract resulted in an increase in the number 
of novel cultivated morphotypes [26].  
Interestingly, fourteen strains exhibited only 92.9–98.2% sequence similarities with validly 
described species. The low sequence similarities suggest that these strains belong to novel 
actinomycete taxa which are further supported by phylogenetic analysis [27] (Figures 2 and 3). These 
putatively novel isolates were affiliated to the genera Rothia, Kocuria, Micrococcus, Brachybacterium, 
Brevibacterium, Microbacterium (suborder Micrococcineae) (Figure 2). The isolates EG4 and EG62 
from Callyspongia sp. and Amphimedon sp., respectively, formed a separate cluster from close 
relatives of the genus Microbacterium. The high sequence similarity (99.8%) of the isolates with only 
three nucleotide differences suggests that they are the same strain although they were isolated from 
different sponge species. The other putatively novel isolates were affiliated with the following genera: 
Mycobacterium and Rhodococcus (suborder Corynebacterineae), Actinokineospora (suborder 
Pseudonocardineae), Streptomyces (suborder Streptomycineae) and Rubrobacter (suborder 
Rubrobacterineae) (Figure 3). Interestingly, isolate RV113 from Aplysina aerophoba exhibited  
92.9% sequence similarities to Rubrobacter radiotolerans as well as to several uncultured clones. 
Phylogenetic analysis revealed that the isolate RV113 forms a distinct clade and the low sequence 
similarity values further suggest that RV113 possibly belongs to a novel genus with Rubrobacter as its 
closest relative. Phenotypic and genotypic characterization will be pursued to validate the taxonomic 
position of this strain as well as the remainder of putatively novel actinomycete isolates cultivated in 
this study. 
Several studies have previously reported on the isolation and diversity of actinobacteria from 
marine sponges. Montalvo et al. [13] showed that actinobacteria are major components of the 
microbial communities of Xestospongia muta and X. testudinaria. Zhang et al. [15] isolated 106 
actinomycete strains representing seven genera from the sponge Hymeniacidon perleve. Additionally, 
181 culturable actinomycetes affiliated with three genera were recovered from five sponges offshore 
China [25]. The microbial diversity of two Red Sea sponges, Hyrtios erectus and Amphimedon sp., 
were recently inspected using cultivation and cultivation-independent analyses. Focused cultivation on 
actinobacteria yielded 35 actinomycetes represented by four genera. [28]. Specifically, strains 
belonging to Actinoalloteichus, Brachybacterium, Brevibacterium, Curtobacterium, Gordonia, 
Kocuria, Micrococcus, Micromonospora, Nocardiopsis, Rhodococcus, Salinispora and Streptomyces 
were previously isolated from marine sponges and may therefore be common components thereof 
[13,15,28–30]. However, none of the strains isolated in our study showed sequence similarities with 
those previously reported from sponges, thus rendering the existence of sponge-specific actinomycete 
clades in the sense of Hentschel et al. [10] unlikely. 
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Figure 2. Neighbor-joining tree of the strains and representative species of the suborder 
Micrococcineae based on nearly complete 16S rRNA gene sequences. Numbers at the 
nodes indicate the levels of bootstrap support based on 1000 resampled data sets. Only 
values greater than 50% are shown. The arrow points to the outgroup consisting of five 
species belonging to Enterobacteriaceae. The scale bar indicates 0.01 substitution per 
nucleotide position. 
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Figure 3. Neighbor-joining tree of the strains and representative species of the suborders 
Corynebacterineae, Pseudonocardineae, Streptomycineae and Rubrobacterineae based on 
nearly complete 16S rRNA gene sequences. Numbers at the nodes indicate the levels of 
bootstrap support based on 1000 resampled data sets. Only values greater than 50% are 
shown. The arrow points to the outgroup consisting of five species belonging to 
Enterobacteriaceae. The scale bar indicates 0.01 substitution per nucleotide position. 
 
2.2. Bioactivity Testing  
A major goal of our study is to establish new sources of antibiotics and other bioactive compounds. 
In order to prevent reisolation of already known compounds, which is a common problem in natural 
products discovery, the 14 putatively novel strains plus six additional ones based on their moderate 
relatedness to known metabolite producers were selected for bioactivity screening. The discovery rate 
of novel compounds is indeed much higher in taxonomically novel than in known strains [31]. The 
antimicrobial activity was assessed by the disc diffusion assay while the anti-parasitic activity was 
Mar. Drugs 2010, 8 
 
406
measured in multi-well plates and is represented as the percentage of growth inhibition in comparison 
to a reference compound. Of the twenty strains tested, ten produced antimicrobially active metabolites 
inhibiting at least one of the test pathogens. Five isolates were capable of inhibiting the growth of 
Gram-positives only, one isolate was active against C. albicans only and one isolate showed activity 
against both groups of pathogens (Table 1). The inhibition was greatest with the Streptomyces sp. 
RV15 against Staphylococcus aureus. Gram-negative bacteria were not susceptible to our isolates. In 
terms of the anti-parasitic activity, four isolates exhibited activity against T. brucei and two isolates 
showed activity against L. major (Table 2). The novel Actinokineospora sp. EG 49 showed highest 
antitrypanosomal potential at 48% growth inhibition. Anti-parasitic activities from marine-derived 
actinomycetes are reported only sporadically. For example, a new thiolactone antibiotic, 
thiolactomycin, from Nocardia strain No. 2-200 showed potent antimalarial and antitrypanosomal 
activities [32]. Additionally, the macrolide antibiotic amphotericin B produced by Streptomyces 
nodosus was used for treatment of leishmaniasis [33].  
Table 1. Antimicrobial activities of sponge-derived actinomycetes. 
Inhibition zone diameter (mm)  
Sponge isolate C. albicans 
S314 
E. faecalis 
JH212 
S. aureus 
8325 
12 0 0 Actinokineospora sp. EG49* 
0 0 13 Dietzia sp. EG67  
0 9 10 Microbacterium sp. EG69* 
0 10 12 Micromonospora sp. RV115  
0 8 12 Rhodococcus sp. EG33* 
0 0 9 Rubrobacter sp. RV113** 
13 11 17 Streptomyces sp. RV15* 
*: putatively new species; **: putatively new genus. 
Table 2. Anti-parasitic activities of sponge-derived actinomycetes. 
Sponge isolate 
% growth inhibition 
L. major T. brucei TC 221 
Actinokineospora sp. EG49* 24 48 
Brevibacterium sp. EG10 0 30 
Gordonia sp. EG50 36 28 
Kocuria sp. RV89* 0 19 
*: putatively new species. 
 
Because crude extracts were tested for bioactivities, the chemical nature of the bioactive compound 
is currently unknown. Nevertheless, some genera, to which the novel isolates belong to, are well 
known and prolific metabolite producers. For example, the genus Streptomyces accounts for about 
80% of all natural products recovered from actinomycetes to date [34]. As one example, Streptomyces 
sannanensis produces new aminoglycoside antibiotics sannamycins A, B and C with potent activities 
Mar. Drugs 2010, 8 
 
407
against Gram-positive bacteria [35]. First organic chemistry analyses of the novel isolate RV15 points 
to entirely novel cyclic peptides which are currently being characterized further. Rhodococcus species, 
of which one putatively novel and bioactive strain was isolated in this study, produce a number of 
commercially interesting and potentially useful products including various types of steroids and 
peptides [36]. For example, two antimycobacterial cyclic peptides, lariatins A and B, were isolated 
from the culture broth of Rhodococcus sp. K01-B0171 [37]. The genus Microbacterium, of which two 
putatively new species were isolated in this study, produces different glycolipids. For example, five 
anti-tumor glycoglycerolipids were obtained from Microbacterium sp., which was isolated from the 
sponge Halichondria panicea [38]. Antimicrobial activities have, to our knowledge, not been reported 
for the genera Actinokineospora, Kocuria and Rubrobacter and the identification of metabolites 
produced by the putative new species of these genera is currently underway. 
In conclusion, considerable actinobacterial diversity was recovered from various marine sponges. 
Altogether 90 actinomycete isolates were affiliated with 18 different genera including 14 putatively 
novel species. One possibly new genus related to Rubrobacter was isolated on M1 agar amended with 
sponge extract, thus highlighting the need for innovative cultivation media. Antibacterial, antifungal, 
antitrypanosomal and antileishmanial activities were reported for 10 of the isolates. Marine sponges 
represent therefore a still largely untapped resource for novel actinomycete diversity as well as for new 
secondary metabolites of therapeutic value. 
3. Experimental 
3.1. Sponge Collection  
The first group of sponges (Aplysina aerophoba, Dysidea avara, D. tupha, Hemimycale culumella, 
Ircinia fasciculata) was collected by SCUBA diving at depths of 3–20 m in the Mediterranean Sea 
(Rovinj, Croatia, (GPS: 27˚47.655 N; 34˚12.904 W) in August 2008. Taxonomic identification was 
performed by W.E.G. Müller and I. Müller (University of Mainz, Germany). The second group 
(Amphimedon sp., Callyspongia sp., C. aff. implexa, Hyrtios erecta, Negombata magnifica, 
Spheciospongia vagabunda) was collected at a depth of 10 m in the Red Sea (Ras Mohamed, Sinai, 
Egypt; (GPS: 27˚47.655 N; 34˚12.904 W) in August 2006. Amphimedon sp. and Hyrtios erecta were 
identified by M. Kelly (National Institute of Water and Atmospheric Research (NIWA) Auckland, 
New Zealand) and the remaining sponges by R.W.M. van Soest (University of Amsterdam, 
Netherlands). Sponges were transferred to plastic bags containing seawater and transported to the 
laboratory. Sponge specimens were rinsed in sterile seawater, cut into pieces of ca. 1 cm3, and then 
thoroughly homogenized in a sterile mortar with 10 volumes of sterile seawater. The supernatant was 
diluted in ten-fold series (10-1, 10-2, 10-3) and subsequently plated out on agar plates. 
3.2. Actinomycete Isolation 
Eight different media [M1 [19], ISP medium 2 [39], Oligotrophic medium (OLIGO) [40], M1 plus [14], 
Actinomycete Isolation Agar (AIA) [41], Marine Agar (MA) [42], Glycerol Asparagine Agar (GAA) 
[41] and R2A Agar [43]] were used for the isolation of actinobacteria. All media were supplemented 
with 0.2 µm pore size filtered cycloheximide (100 µg/mL), nystatin (25 µg/mL) and nalidixic acid  
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(25 µg/mL) to facilitate the isolation of slow-growing actinobacteria. Cycloheximide and nystatin 
inhibit fungal growth, while nalidixic acid inhibits many fast-growing Gram-negative bacteria [14]. All 
media contained Difco Bacto agar (18 g/L) and were prepared in 1 L artificial sea water (NaCl 234.7 g, 
MgCl2.6 H2O 106.4 g, Na2SO4 39.2 g, CaCl2 11.0 g, NaHCO3 1.92 g, KCl 6.64 g, KBr 0.96 g, H3BO3 
0.26 g, SrCl2 0,24 g, NaF 0.03 g and ddH2O to 10.0 L) [44]. To promote the growth of selected 
sponge-associated actinobacteria, 1% “aqueous sponge extract” was added to the autoclaved medium. 
Aqueous sponge extract was prepared by grinding 20 g of sponge biomass in a mortar containing  
20 mL of sterile seawater followed by centrifugation (5000 rpm, 10 min) and sterilized by filtration 
through a 0.2 µm pore size filter. The freshly prepared supernatant served as aqueous sponge extract. 
The inoculated plates were incubated at 30 °C for 6–8 weeks. Distinct colony morphotypes were 
picked and re-streaked until visually free of contaminants. Isolates were inoculated into liquid media 
(M1 or the medium on which colonies were initially isolated). The isolates were maintained on plates 
for short-term storage and long-term strain collections were set up in medium supplemented with 30% 
glycerol at −80 °C. The isolates from Egypt are abbreviated as “EG” and from Rovinj as “RV”.  
3.3. Molecular Identification and Phylogenetic Analysis 
16S rRNA gene amplification, cloning and sequencing were performed according to Hentschel et 
al. [45] using the universal primers 27F and 1492R [46]. Chimeric sequences were identified by using 
the Pintail program [47]. The genus-level affiliation of the sequences was validated using the 
Ribosomal Database Project Classifier [48]. Sequence alignment and phylogenetic analysis were 
performed using the ARB software package [49]. Tree construction was conducted using neighbour-
joining algorithm (Jukes-Cantor correction) with bootstrap values based on 1000 replications. The 16S 
rRNA gene sequences of the putatively novel isolates were deposited in GenBank under the accession 
numbers indicated in parentheses: EG4 (GU318354), EG7 (GU318355), EG33 (GU318356), EG36 
(GU318357), EG37 (GU318358), EG45 (GU318359), EG47 (GU318360), EG49 (GU318361), EG62 
(GU318362), EG69 (GU318363), RV15 (GU318364), RV113 (GU318365), RV13 (GU318366) and 
RV89 (GU318367).  
3.4. Extract Preparation and Anti-infective Activity Screening 
Fourteen strains selected based on phylogenetic novelty and six selected based on their  
affiliation to known metabolite-producers were cultured in 100 mL Erlenmeyer flasks containing  
50 mL of 5 different production media (M1, ISP2, OLIGO, AIA and R2A) for each isolate. The liquid 
cultures were grown for 7–14 days depending on their growth rate at 30 °C while shaking at 150 rpm. 
An equal volume of methanol was added to the liquid cultures for cell lysis and shaking was continued  
(150 rpm, 1 h at room temperature; Shaker SM 30, E. Bühler). The broth was centrifuged in  
50 mL falcon tubes (5000 rpm, 15 min at room temperature; Megafuge 1.0R, Heraeus) and the 
supernatant was stored at 4 °C.  
The in vitro antimicrobial activity testing was carried out using the standard disk diffusion assay [50] 
against pathogenic bacteria (Staphylococcus aureus strain 8325, Enterococcus faecalis strain JH212, 
Escherichia coli strain 536, Pseudomonas aeruginosa strain Nr. 3) and yeast (Candida albicans strain 
S314). Sterile filter disks (6 mm) impregnated with actinomycete extracts were placed on agar plates 
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that had been inoculated with the test pathogen. After 24 h incubation at 37 °C (bacteria) and 30 °C 
(yeast), the antimicrobial potential was quantitatively assessed as diameter of the inhibition zone  
(n = 2). Anti-leishmanial activity was tested following the method of Ponte-Sucre et al. [51]. Briefly, 
this involved the incubation of Leishmania major promastigotes for 24 h at 26 °C, 5% CO2, and 95% 
humidity in the absence or presence of the extracts. Following the addition of Alamar Blue, the plates 
were incubated again and the optical densities were determined after 48 h with a Multiskan Ascent 
enzyme-linked immunosorbent assay (ELISA) reader (Thermo Electron Corporation, Dreieich, 
Germany). Absorbance in the absence of compounds was set as 100% of growth. Amphotericin B was 
used as a reference compound and positive control. Each extract was assayed in duplicate from two 
independent experiments. Anti-trypanosomal activity was tested following the protocols of Huber and 
Koella [52]. Following cultivation of Trypanosoma brucei brucei strain TC 221 in Complete Baltz 
Medium, a defined number of parasites were exposed in 96-well plate test chambers to the extracts. 
The plates were then incubated at 37 °C in an atmosphere of 5% CO2 for 24 h. After addition of 
Alamar Blue, the activity of the extracts was measured by light absorption using MR 700 Microplate 
Reader after 48 h. Absorbance in the absence of compounds was set as 100% of growth. Each extract 
was assayed in duplicate from two independent experiments. 
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